Clinical Trial Update: A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors [Phase 2]

View source ↗

Summary

Phase 2, single-center, single-arm trial of vismodegib in keratocystic odontogenic tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratocystic Odontogenic Tumor

Drugs mentioned

• Vismodegib (Vismodegib)

Snippet

Sponsor: NYU College of Dentistry | Conditions: Keratocystic Odontogenic Tumor | Phase 2 | Status: COMPLETED | Results posted: 2021-02-18